Form 8-K - Current report:
SEC Accession No. 0001213900-23-092089
Filing Date
2023-12-01
Accepted
2023-12-01 17:00:19
Documents
12
Period of Report
2023-11-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea189365-8k_actinium.htm   iXBRL 8-K 27953
  Complete submission text file 0001213900-23-092089.txt   201406

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE atnm-20231130.xsd EX-101.SCH 3033
3 XBRL LABEL FILE atnm-20231130_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE atnm-20231130_pre.xml EX-101.PRE 22371
6 EXTRACTED XBRL INSTANCE DOCUMENT ea189365-8k_actinium_htm.xml XML 3324
Mailing Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017
Business Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017 (646) 677-3870
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 231460343
SIC: 2834 Pharmaceutical Preparations